Breaking News
Get 50% Off 0
📌 New AI-picked stocks coming soon. 3 picks from last month are already up +30%...
Get early access
Close

Faron Pharmaceuticals Oy (FARN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
195.00 +7.50    +4.00%
16:35:59 - Closed. Currency in GBP
Type:  Equity
Market:  United Kingdom
ISIN:  FI4000153309 
SEDOL:  BYMKYR0
  • Volume: 12,055
  • Bid/Ask: 175.00 / 210.00
  • Day's Range: 191.00 - 198.00
Faron Pharmaceuticals Oy 195.00 +7.50 +4.00%

Faron Pharmaceuticals Oy Company Profile

 
Get an in-depth profile of Faron Pharmaceuticals Oy, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

25

Equity Type

ORD

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, it develops receptors involved in regulation of immune response in organ damage and bone marrow regeneration. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Contact Information

Address Joukahaisenkatu 6 B
Turku, 20520
Finland
Phone 358 2469 5151
Fax 358 2469 5152
Web faron.com

Top Executives

Name Age Since Title
Tuomo Patsi 60 2023 Independent Non-Executive Chairman
Juho Markku Jalkanen 46 2017 Founder, CEO & Director
Markku Tapani Jalkanen 70 2006 Non- Executive Director
Huaizheng Peng 62 2015 Board Observer
John Poulos 70 2017 Independent Non-Executive Director
Naval G. Daver - 2024 Member of the Scientific Advisory Board
Toni K. Choueiri - 2024 Member of the Scientific Advisory Board
Tom Powles - 2024 Member of the Scientific Advisory Board
Christophe Massard - 2019 Member of the Scientific Advisory Board
Christine Ann Roth 61 2023 Independent Non-Executive Director
Amer Zeidan - 2024 Member of the Scientific Advisory Board
Mika Kontro - 2024 Member of the Scientific Advisory Board
Marie-Louise Helena Fjallskog 61 2022 Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

FARN Comments

Write your thoughts about Faron Pharmaceuticals Oy
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email